Quantcast

Latest research Stories

2014-07-16 12:28:25

Cognitive function is primary endpoint COPENHAGEN, Denmark, July 16, 2014 /PRNewswire/ -- Bracket is pleased to announce that Biotie Therapies, a specialized drug development company focusing on products for neurodegenerative and psychiatric disorders, has selected the CDR System for use as the primary endpoint for their phase 2 trial of SYN120, an orally administered, dual 5HT6/5HT2a antagonist. SYN120 is in development for the treatment of Parkinson's disease and other cognitive...

2014-07-16 12:27:23

COSTA MESA, Calif., July 16, 2014 /PRNewswire-iReach/ -- WCCT Global, a contract research organization headquartered in Southern Californian announced today the successful completion of a large phase I clinical trial. The study protocol required that WCCT Global enroll 180 patients that would stay in their phase I Clinical Pharmacology Unit for an extended period of time. WCCT Global was able to randomize and accommodate all the needed patient cohorts without delays. WCCTG...

2014-07-16 08:28:30

DCVax®-Direct Phase II Trial Preparations and Manufacturing Expansion Underway BETHESDA, Md., July 16, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the Phase I portion of the Company's Phase I/II DCVax-Direct clinical trial has completed its 36-patient target recruitment, and the Company is now underway with preparations for the Phase II...

2014-07-15 23:07:05

Announcing the Latest Version of the Market-Leading Clinical Conductor CTMS Rochester, NY (PRWEB) July 15, 2014 The Clinical Conductor CTMS team is proud to announce yet another major advancement in CTMS technology. With the latest release of Clinical Conductor, the market-leading CTMS again provides unparalleled advances in both features and functionality designed to give users even greater levels of increased efficiency and maximized profits. Most prominently seen in this release are...

2014-07-15 12:29:33

LONDON, July 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Autism Global Clinical Trials Review, H1, 2014https://www.reportbuyer.com/product/2160177/Autism-Global-Clinical-Trials-Review-H1-2014.htmlAutism Global Clinical Trials Review, H1, 2014SummaryGlobalData's clinical trial report, "Autism Global Clinical Trials Review, H1, 2014" provides data on the Autism clinical trial scenario. This report provides elemental information and data relating to...

2014-07-15 12:29:11

LONDON and WILMINGTON, N.C. and CARY, N.C., July 15, 2014 /PRNewswire/ -- Chiltern and Ockham, two leading full-service contract research organizations (CROs), today announce that Chiltern has acquired 100% of Ockham and that the companies will merge their operations. The combined company will be called Chiltern. Ockham's management team will join the management of the enlarged group, thus ensuring a seamless continuation of high quality services. Chiltern's CEO Jim Esinhart, PhD will be...

2014-07-15 04:22:22

ABERDEEN, Scotland and SINGAPORE, July 15, 2014 /PRNewswire/ -- TauRx Therapeutics Ltd [http://www.taurx.com ] today announced it has achieved its target enrolment of 833 subjects into one of its two ongoing multi-centre Phase III clinical trials of LMTX(TM) [http://taurx.com/lmtx-for-ad ], a tau aggregation inhibitor, for the treatment of Alzheimer's Disease [AD]. This placebo-controlled clinical trial (Protocol TRx-237-015 [http://taurx.com/015-clinical-study.html ]) has...

2014-07-14 23:04:05

Key Questions & Memorable Quotes from #eCongress Toronto, Canada (PRWEB) July 14, 2014 Throughout this past June 100s of mid-to-senior level executives from across the clinical trials space, representing 38 countries globally, registered for Xtalks 1st Annual eCongress webinar series entitled “Optimizing Patient Participation in Clinical Trials. Attract. Engage. Retain.” This well-attended eCongress kicked off with internationally renowned R&D expert, Ken Getz, of Tufts CSDD,...

2014-07-14 12:27:06

Researchers to Use IBM Blue Gene/Q Supercomputer for Computational Drug Design and Discovery RESEARCH TRIANGLE PARK, N.C., July 14, 2014 /PRNewswire/ -- Cloud Pharmaceuticals, Inc., a therapeutics company focused on cloud-based drug design and development, announced today the expansion of its drug design and development program. The company has been granted supercomputing time at Argonne National Laboratory to design inhibitors of multiple parasitic targets. Through a...

2014-07-11 08:24:57

SYDNEY and BEDMINSTER, N.J., July 11, 2014 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) today provided feedback on its 9 July End-of-Review (EOR) meeting with the United States Food and Drug Administration (FDA). The meeting was held to discuss the feasibility and requirements for approving Moxduo, an immediate release Dual Opioid(®), for the treatment of moderate to severe acute pain. In advance of the meeting, QRxPharma outlined several questions to discuss with...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related